Application of Poly-herbal Powder for Treating Acne Vulgaris
1 other identifier
interventional
42
1 country
1
Brief Summary
Acne is a common problem in adolescence to young adult. But there is no such remedy available for acne treatment which has no side effects. Different types of herbs powder has been using in patients with acne vulgaris in the traditional practice of Indian subcontinent as single form or compound. Scientific evidence have shown many herbs has no known side effects and effective on acne. These herbs have antibacterial, anti-inflammatory and anti-oxidant effects. So, This study is intended to find out an inexpensive and safe alternative by using some common herbs such as Azadirachta indica, Curcuma longa, Lens culinaris Mentha arvensis and Trigonella foenum-graecum. The aim of the study is to evaluate the clinical efficacy of Poly herbal powder (PHP) for treating patients with acne vulgaris. Total of 42 adults with acne vulgaris was recruited for this study. Study subjects was included both of male and female with age limit of 18 to 35 years. Duration of study is 05 months with "day one advertisement" for screening followed by randomization for the treatment. The duration of active participation of each study subject was 3 consecutive weeks or 21days. Difference of baseline and post intervention mean by Total lesion Count (TLC) compared with placebo and assesses the % of reduction of acne based on The Global Acne Grading System (GAGS) score. Safety assessment was obtained from the incidence and type of adverse events during study period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 15, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 12, 2021
CompletedFirst Submitted
Initial submission to the registry
June 20, 2021
CompletedFirst Posted
Study publicly available on registry
July 2, 2021
CompletedJuly 2, 2021
July 1, 2021
12 days
June 20, 2021
July 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Total Lesions Count (TLC)
Total Lesions Count (TLC) = Comedones + Papules + Pastules, before and after intervention will be presented as percentage as well as mean and standard deviation.
03 weeks
Secondary Outcomes (2)
Change in The Global Acne Grading System score
03 weeks
Change in non-inflammatory and inflammatory lesions count
03 weeks
Study Arms (2)
Intervention Arm
EXPERIMENTALPoly herbal powder (PHP)
Placebo Arm
PLACEBO COMPARATORPowder of Cicer arietinum
Interventions
Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
Eligibility Criteria
You may qualify if:
- Men and women both aged between 18-35 years
- Presenting minimum 5 acne lesions (whiteheads, blackheads, papules, pustules, nodules)
- Study subject who will be agreed with Online informed consent.
You may not qualify if:
- Have infected acne lesions
- If study subject suffers from any serious medical conditions such as uncontrolled hypertension, diabetes mellitus, past or current malignancy, liver or kidney dysfunction, active pulmonary tuberculosis other severe dermatitis, or any infectious or systemic diseases.
- Use of a topical medication containing steroids for the treatment of skin disease more than once per month.
- Hypersensitive skin.
- Erythema, or telangiectasia at the test site.
- Use of the same or similar cosmetics (or pharmaceutical) on the test site within three months of screening.
- Having undergone a skin peeling or having wrinkles removed within six months.
- Any other reasons of unsuitability for the clinical trial at the discretion of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hamdard University Bangladesh
Munshiganj, 1510, Bangladesh
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dr.Md. S Uddin, BUMS
MPH student, Hamdard University Bangladesh
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 20, 2021
First Posted
July 2, 2021
Study Start
April 3, 2021
Primary Completion
April 15, 2021
Study Completion
May 12, 2021
Last Updated
July 2, 2021
Record last verified: 2021-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
- Time Frame
- Starting 6 months after publication.
- Access Criteria
- Request by email.
All Individual Participant Data that underlie results in a publication